Socioeconomic Paradigms Influencing the Allocation of Oncological Therapeutics: A Comparative Study
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5885Keywords:
mRNA vaccines, Cancer immunotherapy, Cost-benefit analysis, Socioeconomic factors, Clinical trials, Efficacy, Immunogenicity, Manufacturing costs, Distribution costs, Accessibility, Optimal allocation, Comparative effectiveness, Patient outcomes, Neoplasms, Tumor heterogeneity, Combination therapy, Preventative applications, Infrastructure, Generalizability, Long-term efficacy, Population representation, Confidence intervals, Modularity, Scalability, Rapid production, Adaptability, Logistical flexibility, Need-based distribution, Underrepresented groups, Preventable mortality, Premature mortality, Economic disparities, Social disparitiesAbstract
Cancer presents a formidable globalized public health challenge with extensive socioeconomic ramifications. This paper investigates the socioeconomic optimality of mRNA-based oncological platforms concerning cancer amelioration. Quantitative analysis discerned the socioeconomic effectiveness of mRNA candidates. Clinical immunogenicity data demonstrated efficacy variability amongst platforms. Cost-benefit assessment discerned CV9202's superior cost-effectiveness, representing socioeconomic optimality. These methodological developments provide a comparative basis to contextualize implementation gaps and accessibility disparities. Socioeconomic cognizance permits tailored therapeutic accommodation for economic constraints, improving patient outcomes through optimized distribution. Further generalization necessitates extensive efficacy data over prolonged timeframes encompassing long-term immunological durability. Societal stigmatization presents additional complications. This research delineates an analytical paradigm to discern optimal therapeutic allocation given socioeconomic circumstances. Improved patient-provider relations may arise from responsive distribution models sensitive to socioeconomic factors. Optimal distribution has advantageous implications for stakeholders. Future research could assess preventative applications, combination therapies, infrastructural variables, and extensive candidates. In conclusion, this methodology demonstrates means of optimizing distribution congruent with socioeconomic factors to improve accessibility and cancer outcomes through cost-effective therapeutic platforms like mRNA vaccination.
Downloads
References or Bibliography
Miao, L., Zhang, Y., & Huang, L. (2021, February 25). MRNA vaccine for cancer immunotherapy - molecular cancer. BioMed Central. Retrieved April 29, 2023, from https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01335-5
Beatty, G. L., & Gladney, W. L. (2015, February 15). Immune escape mechanisms as a guide for cancer immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. Retrieved May 1, 2023, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334715/
Moderna and Merck announce mrna-4157/V940, an investigational personalized mrna cancer vaccine, in combination with keytruda(r) (pembrolizumab), met primary efficacy endpoint in phase 2B KEYNOTE-942 trial. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial. (2022, December 13). Retrieved May 1, 2023, from https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx
Huang, L., Zhang, Y., & Miao, L. (2021, February 25). A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mrnas ... mRNA vaccine for cancer immunotherapy. Retrieved May 1, 2023, from https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3092
Miao, L., Zhang, Y., & Huang, L. (2021, February 25). MRNA vaccine for cancer immunotherapy - molecular cancer. BioMed Central. Retrieved May 1, 2023, from https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01335-5/tables/1
Miao, L., Zhang, Y., & Huang, L. (2021, February 25). MRNA vaccine for cancer immunotherapy - molecular cancer. BioMed Central. Retrieved May 1, 2023, from https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01335-5/tables/1
Miao, L., Zhang, Y., & Huang, L. (2021, February 25). MRNA vaccine for cancer immunotherapy - molecular cancer. BioMed Central. Retrieved May 1, 2023, from https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01335-5/tables/3
Miao, L., Zhang, Y., & Huang, L. (2021, February 25). MRNA vaccine for cancer immunotherapy - molecular cancer. BioMed Central. Retrieved May 1, 2023, from https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01335-5/tables/2
Clegg, L. X., Reichman, M. E., Miller, B. A., Hankey, B. F., Singh, G. K., Lin, Y. D., Goodman, M. T., Lynch, C. F., Schwartz, S. M., Chen, V. W., Bernstein, L., Gomez, S. L., Graff, J. J., Lin, C. C., Johnson, N. J., & Edwards, B. K. (2009, May). Impact of socioeconomic status on cancer incidence and stage at diagnosis: Selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer causes & control : CCC. Retrieved May 1, 2023, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711979/
Joseph M. Unger, P. D. (2018, August 17). Survival outcomes for rural vs urban patients with cancer in clinical trials. JAMA Network Open. Retrieved May 1, 2023, from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2696871
Hovanec, J., Siemiatycki, J., Conway, D. I., Olsson, A., Stücker, I., Guida, F., Jöckel, K.-H., Pohlabeln, H., Ahrens, W., Brüske, I., Wichmann, H.-E., Gustavsson, P., Consonni, D., Merletti, F., Richiardi, L., Simonato, L., Fortes, C., Parent, M.-E., McLaughlin, J., … Behrens, T. (2018, February). Lung cancer and socioeconomic status in a pooled analysis of case-control studies. PLOS ONE. Retrieved May 1, 2023, from https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0192999
Wilgenhof, S., Corthals, J., Heirman, C., Neyns, B., & Thielemans, K. (2015, November 4). Clinical trials with mrna electroporated dendritic cells for stage III/IV Melanoma Patients - Journal for immunotherapy of cancer. BioMed Central. Retrieved May 1, 2023, from https://jitc.biomedcentral.com/articles/10.1186/2051-1426-3-S2-P211
Light, D. W., & Lexchin, J. (2021, November 3). The costs of coronavirus vaccines and their pricing. The Costs of Coronavirus Vaccines and Their Pricing. Retrieved May 2, 2023, from https://journals.sagepub.com/doi/full/10.1177/01410768211053006
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, &O., Vormehr, M., & Kranz, L. M. (2021, April 15). MRNA therapeutics in cancer immunotherapy - molecular cancer. BioMed Central. Retrieved May 1, 2023, from https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01348-0
Published
How to Cite
Issue
Section
Copyright (c) 2023 Brandon Adams; Marydell Joyce
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
